PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-5.69%
Revenue decline while Medical - Pharmaceuticals median is 3.31%. Seth Klarman would investigate if market share loss is temporary.
-5.36%
Cost reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive advantage potential.
-7.03%
Gross profit decline while Medical - Pharmaceuticals median is 5.23%. Seth Klarman would investigate competitive position.
-1.43%
Margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
24.46%
Other expenses change of 24.46% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify efficiency.
1.09%
Operating expenses growth 50-90% of Medical - Pharmaceuticals median of 1.27%. Mohnish Pabrai would examine discipline.
-4.38%
Total costs reduction while Medical - Pharmaceuticals median is 1.80%. Seth Klarman would investigate advantages.
-12.12%
Interest expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
10.12%
D&A growth exceeding 1.5x Medical - Pharmaceuticals median of 0.83%. Jim Chanos would check for overinvestment.
-21.69%
EBITDA decline while Medical - Pharmaceuticals median is 6.78%. Seth Klarman would investigate causes.
-16.97%
EBITDA margin decline while Medical - Pharmaceuticals median is 0.64%. Seth Klarman would investigate causes.
-30.94%
Operating income decline while Medical - Pharmaceuticals median is 8.45%. Seth Klarman would investigate causes.
-26.77%
Operating margin decline while Medical - Pharmaceuticals median is 0.38%. Seth Klarman would investigate causes.
238.05%
Other expenses change of 238.05% versus flat Medical - Pharmaceuticals. Walter Schloss would verify control.
-15.31%
Pre-tax income decline while Medical - Pharmaceuticals median is 7.15%. Seth Klarman would investigate causes.
-10.21%
Pre-tax margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-14.76%
Tax expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
-15.78%
Net income decline while Medical - Pharmaceuticals median is 12.48%. Seth Klarman would investigate causes.
-10.70%
Net margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-15.82%
EPS decline while Medical - Pharmaceuticals median is 12.36%. Seth Klarman would investigate causes.
-15.82%
Diluted EPS decline while Medical - Pharmaceuticals median is 12.53%. Seth Klarman would investigate causes.
-0.00%
Share count reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate strategy.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate strategy.